Mode
Text Size
Log in / Sign up

Neoadjuvant chemoimmunotherapy requires multidisciplinary interpretation of ctDNA and imaging to manage biomarker discordanceNew Findings Help Interpret Complex Lung Cancer Treatment Results

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret ctDNA clearance as a molecular response rather than definitive proof of tissue eradication in NSCLC.

This narrative review explores the complexities of interpreting biomarker discordance in patients with resectable non-small cell lung cancer undergoing neoadjuvant chemoimmunotherapy. The review synthesizes findings regarding immune ecologies, ctDNA dynamics, and imaging outcomes to guide clinical decision-making.

Key findings indicate that paired tissue studies reveal distinct primary and nodal immune ecologies, with response-associated lymphoid and myeloid programs. Regarding molecular monitoring, the authors emphasize that presurgical ctDNA clearance signifies a molecular response but does not serve as definitive proof of tissue eradication. Furthermore, the review notes that inflammatory and reparative tissue changes can sustain imaging abnormalities even after tumor regression.

The authors acknowledge the limitations of the narrative review approach. Clinical application of these findings suggests that multidisciplinary teams should use these principles to navigate discordance between pathology, ctDNA, and imaging. This approach aims to better inform management decisions when individual biomarkers provide conflicting signals regarding treatment response.

How this fits prior evidence

This review addresses a gap in the management of neoadjuvant chemoimmunotherapy for stage II non-small cell lung cancer, which has shown promising pathologic response and survival. It specifically addresses the complexity of tissue remodeling and the limitations of current molecular detection. By highlighting that ctDNA clearance is not proof of tissue eradication and that imaging may reflect inflammatory changes, it provides specific nuances to the broader context of complex environments influencing tumor persistence.

This review looks at how doctors can better understand different types of data when treating patients with resectable non-small cell lung cancer. Specifically, it looks at how tissue samples, blood tests, and imaging results can sometimes give different signals after a patient receives neoadevuant chemoimmunotherapy.

Researchers found that while clearing certain markers in the blood is a sign of a molecular response, it does not prove that all cancer cells have been removed from the tissue. Additionally, some imaging results might show abnormalities even after a tumor has shrunk. This can happen because the body is undergoing inflammatory or reparative changes in the area.

Because these different tests can sometimes provide conflicting information, it is important for medical teams to look at all data together. This review provides a framework for doctors to better interpret these mixed signals. This helps them make more informed decisions about the next steps in a patient's care.

What this means for you:
Different tests like blood work and imaging can provide different signals during lung cancer treatment.

Common questions

Does a clear blood test mean the cancer is gone?

A clear ctDNA result in the blood indicates a molecular response to treatment. However, the study notes that this is not proof that all cancer tissue has been eradicated. Doctors must look at other factors to determine the status of the cancer.

Why might scans show issues after the tumor shrinks?

Imaging can sometimes show abnormalities even after a tumor has regressed. These findings may be caused by inflammatory or reparative tissue changes rather than remaining cancer. It is important to interpret these images carefully in a clinical setting.

How do doctors use these different tests together?

Doctors use these findings to better interpret discordance between pathology, blood tests, and imaging. By understanding why these tests might give different signals, medical teams can make more informed decisions for patients with non-small cell lung cancer.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedNov 2026
View Original Abstract ↓
Neoadjuvant chemoimmunotherapy can produce uneven responses across the primary tumour, regional lymph nodes, and occult systemic disease. Pathology, circulating tumour DNA (ctDNA), and imaging capture different consequences of this response, so their disagreement can contain clinically relevant biological information. This structured narrative review examines same-patient evidence in resectable non-small cell lung cancer and interprets discordance through anatomical compartment, sampling time, and local immune context. Paired tissue studies show distinct primary and nodal immune ecologies and response-associated lymphoid and myeloid programmes. Spatial clonality and unequal shedding shape the circulating signal, while inflammatory and reparative tissue changes can sustain imaging abnormalities after tumour regression. These observations inform four proposed principles for multidisciplinary interpretation. Separate primary and nodal reporting preserves compartment-specific response information. Presurgical ctDNA clearance indicates molecular response, not proof of tissue eradication. Confirmed postoperative molecular conversion provides a rationale for reassessing current disease status. For imaging conflicts that could alter curative-intent management, lesion-level review can identify when tissue confirmation would be feasible and decision-changing. A postoperative pathology–molecular residual disease matrix organises research questions while preserving nodal findings, unresolved lesions, and serial molecular trajectory. The immediate contribution is to identify which additional observation can resolve a consequential conflict; treatment adaptation then requires evidence that acting on the result benefits patients. Biomarker discordance is therefore an interpretive problem with biological content, rather than a reason to let the most favourable test define the entire response.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.